Nitrosamine impurity control has moved from an emergency response to a standing element of pharmaceutical quality systems. Marketing authorization holders are expected to hold a current risk assessment for each product, to confirm that assessment with testing where risk is identified, and to update it when anything material changes in the manufacturing route.
The practical difficulty is that the holder rarely controls the information the assessment depends on. Route of synthesis, solvents and reagents, recovered materials, catalysts, equipment shared with other products, and the supplier’s own upstream vendors all sit with the drug substance manufacturer. What the holder can control is the contract, and whether that contract obliges the supplier to provide what the assessment requires and to say something when the process changes.
This datasheet sets out the commitments worth holding in supplier agreements, the recurring obligations they create on both sides, and the record structure that lets a quality team answer a regulator’s question without a document hunt. The contractual work is modest in volume and concentrated in a small number of agreements, which makes it one of the more tractable parts of the problem.
The commitments that matter in a supplier agreement
Nitrosamine-related duties tend to be scattered across quality and commercial documents. These are the five worth isolating and tracking as named obligations.
- Process and route disclosure, the supplier’s duty to disclose the synthetic route, solvents, reagents and any recovered or recycled materials in enough detail to support a risk assessment.
- Change notification with scope, advance notice of changes to route, raw material source, equipment, site or subcontractor, with the notice period and the escalation contact both named.
- Testing responsibility, which party performs confirmatory testing, using which validated method, at what frequency, and against which acceptance limit.
- Data provision on request, the supplier’s obligation to provide impurity data, method details and supporting studies within a defined turnaround when a reassessment is triggered.
- Cost and timing allocation, who pays for testing, method development and any investigation, since this is a commercial question that stalls technical work when it is unresolved.
Each commitment is straightforward to draft. What makes the difference is whether it exists as a record that somebody monitors. A change notification clause with a 90 day notice period is worth nothing if notices arrive at a purchasing mailbox and no one has an obligation to route them into a reassessment. The distinction between a clause that exists and an obligation that is monitored is the whole of the compliance question here.
A risk assessment is valid only for the process it described. The events that invalidate it, a route change, a new raw material source, a site transfer, a change of upstream vendor, all originate outside your organization. Defining those triggers in the contract, and building an intake that turns each notice into a dated reassessment task, is what keeps the assessment current between regulatory submissions.
Common gaps in practice
The pattern is consistent across mid-sized and large holders alike, and it is less about drafting quality than about what happens after signature.
- Duties live in three documents. Quality agreement, supply agreement and technical appendix each say something about testing, and they are not always consistent about who does what.
- Testing frequency is unstated. The agreement commits to testing without saying how often, which becomes a negotiation every time a batch is released.
- Notification scope is too narrow. Clauses that cover changes to the finished specification miss the upstream process changes that actually drive nitrosamine risk.
- Upstream suppliers are out of reach. Without flow-down obligations, the drug substance manufacturer’s own vendor changes never surface, and that is often where the risk originates.
- Evidence is assembled reactively. When a regulator asks for the current assessment and its supporting data, the team reconstructs the file rather than retrieving it.
Five steps to contract-backed nitrosamine control
Step 1, Build the product to supplier map
For each marketed product, identify the drug substance supplier, any intermediate suppliers and the contract manufacturers involved. This map is the scope of the contractual work, and it is frequently incomplete because products acquired through licensing or acquisition carry agreements the quality team has never read.
Step 2, Extract the existing commitments
Run extraction across those agreements to pull change notification, testing, data provision and audit clauses into structured fields. Compare what each agreement actually says against what your assessment methodology assumes. The gaps identified here are the agenda for the next amendment cycle.
Step 3, Define reassessment triggers explicitly
Write down the events that require the risk assessment to be revisited and make sure the contractual notification scope covers each one. Where a supplier agreement is narrower than your trigger list, either amend it or record the residual risk and compensate with more frequent testing.
Step 4, Create an intake for supplier notices
Route every supplier change notice to a single point with a mandatory assessment step and a defined turnaround. Record the outcome against the obligation, including a decision that no reassessment was needed. A documented negative decision is evidence; an undocumented one is a gap.
Step 5, Hold the evidence against the obligation
Store test results, method validation records, supplier data packages and assessment conclusions on the obligation record rather than in a separate document system. When the question is whether a commitment was met on a given date, the answer and its proof should sit together.
See supplier testing duties tracked to closure
Watch how testing frequency, method and data provision commitments become monitored records with named owners.
Why this is an obligation management problem
Nitrosamine control has the defining features of a post-signature obligation problem: duties split across parties, recurring rather than one-time, and evidenced by artifacts that accumulate over years. The same structure applies to every GxP commitment in a supplier agreement, as set out in GxP supplier qualification, contract controls that hold. Holding these as tracked records with owners and dates, rather than as clauses in an executed file, is the approach described in Obligation Management for Life Sciences, and it is what makes the evidence retrievable when an inspector asks. It also makes the gaps visible in advance, which is the only useful time to find out that an agreement does not oblige what your methodology assumes.
Obligation, trigger and evidence
A register for nitrosamine commitments should carry the same four columns for every entry, whichever party holds the duty.
| Obligation | Party | Trigger or cadence | Evidence retained |
|---|---|---|---|
| Route and process disclosure | Supplier | At qualification and on change | Process description and revision date |
| Change notification | Supplier | Event driven, per notice period | Notice and receipt record |
| Risk assessment refresh | Holder | On trigger and periodically | Assessment document with rationale |
| Confirmatory testing | As allocated | Defined frequency | Test results and method validation |
| Data provision on request | Supplier | Within agreed turnaround | Data package and transmission record |
Nitrosamine risk is a long-running control problem rather than a project with an end date. The technical work is well understood by now; what separates organizations is whether their supplier agreements oblige the right disclosures and whether anyone is tracking those obligations between submissions. A register with owners, triggers and retained evidence turns a regulator’s question from a research exercise into a retrieval, and it surfaces the agreements that need renegotiating before a change makes the gap urgent. Teams that build the register once find it absorbs the next impurity class without redesign, which matters because nitrosamines are unlikely to be the last of these.
For related guidance, see The quality leader’s guide to pharma quality agreements, The quality leader’s guide to CDMO quality agreements and The sponsor’s guide to CRO master service agreements.
